Melanoma Evidence & Self-Care · education / decision-support

← Evidence library

BIB_133

De Giorgi V et al. Propranolol for Off-label Treatment of Patients With Melanoma: Cohort Study. JAMA Oncology 2018. PMID 28973254. n = 53 PROP + 79 No-PROP, stage IB-IIIA cutaneous melanoma, propranolol 80 mg daily; PFS benefit signal. [Tasks: 12] Tier: 3 Grade: B Retrieved: 2026-05-07

Evidence grade
B
Tier
3
Cited by tasks
12
Identifiers
PMID:28973254

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_133/findings.md (research corpus). This page is a short context summary — not individualised medical advice.